Several tacrolimus to belatacept conversion protocols have been described in the literature using various forms of tapering tacrolimus over days to weeks. Biopsy proven acute rejection (BPAR) post conversion ranged from 3-33%. The purpose of this study was to assess short-term efficacy of stopping tacrolimus at belatacept initiation while using a more reduced initial phase regimen than described previously in patients within 6 months of transplant.
No takes yet. Share an insight, caveat, or question.
Mattiazzi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: